Literature DB >> 23515714

Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.

M Deuschle1, F Paul, M Brosz, N Bergemann, M Franz, J Kammerer-Ciernioch, M Lautenschlager, F Lederbogen, D Roesch-Ely, M Weisbrod, K G Kahl, J Reichmann, J Gross, J Umbreit.   

Abstract

PURPOSE: Patients with severe mental illness are at high risk for metabolic and cardiac disorders. Thus, monitoring of cardiovascular risks is imperative and schedules for screening for lipids, glucose, body mass index (BMI), waist-hip ratio and blood pressure have been developed. We intended to analyze screening for metabolic disorders in German patients with schizophrenia spectrum disorders in routine psychiatric care.
METHODS: We included 674 patients with any F2 diagnosis in out- and inpatient settings and analyzed metabolic screening procedures as practiced under conditions of usual care.
RESULTS: Except BMI (54 %), all other values were documented only in a minority of patients: waist circumference (23 %), cholesterol (28 %), fasting glucose (19 %), triglycerides (25 %) and blood pressure (37 %). We found evidence for less than perfect quality of blood pressure measures. The group of patients who met the individual metabolic syndrome ATP III criteria was comparable to the US CATIE trial.
CONCLUSIONS: We conclude that frequency and quality of metabolic monitoring in German in- and outpatients settings are not in accordance with the respective recommendations. Similar to previous reports we found evidence for a high prevalence of metabolic disturbances in German patients with schizophrenia spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23515714     DOI: 10.1007/s00127-013-0676-0

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  35 in total

1.  Family history of type 2 diabetes in schizophrenic patients.

Authors:  S Mukherjee; D B Schnur; R Reddy
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

2.  Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans.

Authors:  Lydia A Chwastiak; Robert A Rosenheck; Lewis E Kazis
Journal:  Psychosomatics       Date:  2011 May-Jun       Impact factor: 2.386

Review 3.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

Review 4.  Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.

Authors:  M De Hert; D Vancampfort; C U Correll; V Mercken; J Peuskens; K Sweers; R van Winkel; A J Mitchell
Journal:  Br J Psychiatry       Date:  2011-08       Impact factor: 9.319

5.  Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort.

Authors:  Steve Brown; Clemence Mitchell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-05-11       Impact factor: 4.328

6.  The unhealthy lifestyle of people with schizophrenia.

Authors:  S Brown; J Birtwistle; L Roe; C Thompson
Journal:  Psychol Med       Date:  1999-05       Impact factor: 7.723

7.  The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Authors:  Bruno Falissard; Mauro Mauri; Ken Shaw; Tilman Wetterling; Adam Doble; Agnès Giudicelli; Marc De Hert
Journal:  Int Clin Psychopharmacol       Date:  2011-11       Impact factor: 1.659

8.  The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.

Authors:  John W Newcomer; Henry A Nasrallah; Antony D Loebel
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

9.  Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.

Authors:  Antoni Sicras-Mainar; Milagrosa Blanca-Tamayo; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda
Journal:  Eur Psychiatry       Date:  2007-09-29       Impact factor: 5.361

10.  A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.

Authors:  Paul Mackin; David R Bishop; Helen M O Watkinson
Journal:  BMC Psychiatry       Date:  2007-06-25       Impact factor: 3.630

View more
  5 in total

1.  [Cardiac and metabolic risk factors in severe mental disorders. Task of a prevention manager].

Authors:  F Lederbogen; P Schwarz; S Häfner; U Schweiger; M Bohus; M Deuschle
Journal:  Nervenarzt       Date:  2015-07       Impact factor: 1.214

Review 2.  [Somatic morbidity in the mentally ill].

Authors:  W Hewer; F Schneider
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

3.  QLiS-SF: Development of a short form of the quality of life in schizophrenia questionnaire.

Authors:  T Senin; M Franz; M Deuschle; N Bergemann; J Kammerer-Ciernioch; M Lautenschlager; T Meyer
Journal:  BMC Psychiatry       Date:  2017-04-27       Impact factor: 3.630

4.  Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study.

Authors:  Jung Sun Lee; Jun Soo Kwon; Daeho Kim; Sung-Wan Kim; Jae-Jin Kim; Jong-Hoon Kim; Hee Jung Nam; Seunghyong Ryu; Il Ho Park; Suk Kyoon An; Hong-Seok Oh; Seunghee Won; Kanguk Lee; Kyu Young Lee; Seung-Hwan Lee; Yu Sang Lee; Jung-Seo Yi; Kyung Sue Hong; Yeon Ho Joo
Journal:  Psychiatry Investig       Date:  2016-12-29       Impact factor: 2.505

5.  Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study.

Authors:  J Westman; S V Eriksson; M Gissler; J Hällgren; M L Prieto; W V Bobo; M A Frye; D Erlinge; L Alfredsson; U Ösby
Journal:  Epidemiol Psychiatr Sci       Date:  2017-06-05       Impact factor: 6.892

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.